# Fluticasone furoate + Umeclidinium + Vilanterol

## Trelegy Ellipta 92/55/22 mcg Inhalation Powder

##### 

| 藥品代碼   | ETRE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | Chronic obstructive pulmonary disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 用法用量   | Oral inhalation: Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily (maximum dose: 1 inhalation/day)                                                                                                                                                                                                                                                                                                                                                                    |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 禁忌       | Hypersensitivity to fluticasone， umeclidinium， vilanterol， or any component of the formulation; severe hypersensitivity to milk proteins                                                                                                                                                                                                                                                                                                                                                                                              |
| 副作用     | 1% to 10%: Headache (4%)， voice disorder (>=1%)， Diarrhea (2%)， dysgeusia (2%)， constipation (>=1%)， oral candidiasis (>=1%)， gastroenteritis (1%)， Urinary tract infection (>=1%)， Influenza (>=1%)， Back pain (4%)， arthralgia (>=1%)， Pneumonia (8%)， bronchitis (>=1%)， pharyngitis (>=1%)， rhinitis (>=1%)， sinusitis (>=1%)， upper respiratory tract infection (>=1%)， cough (1%)， oropharyngeal pain (1%) Frequency not defined:Paradoxical bronchospasm <1%， postmarketing， and/or case reports: Anaphylaxis |
| 孕期建議   | Uknown 沒有資料                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 哺乳期建議 | Unknown 沒有資料                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

